Tag:

National Venture Capital Association

Latest Headlines

Latest Headlines

VC's biotech investing slips in Q3, but '14 still looks like a record-breaker

Last quarter biotech attracted a whopping $1.8 billion in new venture cash, the biggest quarter since 2005.

Q4 venture haul pushes 2013 biotech investing past $4.5B

U.S. biotech companies attracted a bountiful $1.3 billion venture haul in the fourth quarter of 2013, pushing the total for the year to $4.53 billion--well ahead of 2012's mark of $4.19 billion and a hopeful sign of continued activity headed into 2014.

A (now) broken record: Med tech VC funding dropped again in 2013

In 2013, VCs spent $2.1 billion on 308 medical device investment deals, representing a 17% plunge in dollars and 4% drop in deals compared to the year before, according to the latest MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association, based on Thomson Reuters data.

NVCA starts 2014 with a hopeful wrap-up on the biotech IPO party

There were a few misfires on the biotech IPO front in the fourth quarter of 2013, but the National Venture Capital Association says it tallied 6 newly minted public drug developers in the period, winding up a big year.

Top Med Tech Investments of Q3

In this list of the top 10 med tech VC deals for Q3, one thing is painfully clear: Early-stage innovators are out of the picture. The winning companies are relatively far along, looking to expand...

Top 10 Med Tech Investments of Q2

An interesting thing happened on the way through 2013: Biotechnology venture investing began to see a healthy rebound in the second quarter, but medical device investing stayed essentially flat compared to the first three months of the year. Check out the report >>

Med tech VC investing remains sluggish; biotech surges

Venture capital investment in medical device companies declined slightly during the 2013 second-quarter, even as it soared significantly for biotechnology and many other industries.

UPDATED: Biotech rattled as Q1 first-time VC deals plunge to 18-year low

The VC industry turned in bleak numbers for biotech deal-making in the first quarter of 2013, with one key measure of early-stage activity in the life science sector falling to its lowest level in almost 18 years.

Device company VC funding continues its plunge

Med Tech venture investing continued its painful decline in the 2013 first quarter, dropping a whopping 20% in dollars and 10% in deal numbers versus last the three months of 2012, according to the latest MoneyTree survey.

Medical device VC cash plunged 13% in 2012

In 2012, the medical device sector saw a 13% dollar-value drop from the year before and a 15% decline in the number of deals, according to the latest MoneyTree report. Read more >>